Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05BYA
|
|||
| Former ID |
DCL001115
|
|||
| Drug Name |
NVP-AUY922
|
|||
| Synonyms |
Luminespib; 747412-49-3; AUY922; VER-52296; AUY-922; UNII-C6V1DAR5EB; AUY922 (NVP-AUY922); Luminespib (NVP-AUY922); NVP-AUY 922; 5-(2,4-dihydroxy-5-isopropylphenyl)-N-ethyl-4-(4-(morpholinomethyl)phenyl)isoxazole-3-carboxamide; C6V1DAR5EB; Luminespib (AUY-922, NVP-AUY922); CHEBI:83656; 5-[2,4-DIHYDROXY-5-ISOPROPYLPHENYL]-N-ETHYL-4-[4-(4-MORPHOLINYLMETHYL)PHENYL]-3-ISOXAZOLECARBOXAMIDE; AK174786; 5-[2,4-Dihydroxy-5-(1-Methylethyl)phenyl]-N-Ethyl-4-[4-(Morpholin-4-Ylmethyl)phenyl]isoxazole-3-Carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Multiple myeloma [ICD-11: 2A83; ICD-10: C90; ICD-9: 203] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Vernalis; Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H31N3O5
|
|||
| Canonical SMILES |
CCNC(=O)C1=NOC(=C1C2=CC=C(C=C2)CN3CCOCC3)C4=CC(=C(C=C4O)O)C(C)C
|
|||
| InChI |
1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)
|
|||
| InChIKey |
NDAZATDQFDPQBD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 747412-49-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15083415, 39155921, 46484819, 49689000, 76608378, 99436965, 103556527, 124756976, 125163781, 126581936, 126738735, 131480668, 135727472, 136367275, 136367858, 136920354, 137245317, 138971951, 140671853, 143499493, 144116295, 152105921, 152237713, 152258028, 152258131, 152344085, 160646970, 162011585, 162037415, 162202735, 163642590, 164044840, 164193951, 174530564, 177748703, 185975634, 188899501, 198974570, 223401065, 223448353, 223680473, 228770821, 249814513, 251963184, 251971001, 252160237, 252215929
|
|||
| ChEBI ID |
CHEBI:83656
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01854034) Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027019) | |||
| REF 3 | Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. | |||
| REF 4 | The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth. Mol Cancer Ther. 2013 Jun;12(6):890-900. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.